Recent Posts
- MicroRNA-Mediated Metastasis Suppression
- A New Explanation Of ‘Asian Paradox’
- Toward Bold New Anti-cancer Medicines
- Celsion And Yakult Honsha Announce Treatment Of First Patient In Japan In Celsion’s Global Phase III ThermoDox(R) Trial For Primary Liver Cancer
- $6.5 Million Gift To UCSF From Irwin And Joan Jacobs For Head And Neck Cancer Research
Random Posts
- Boehringer Ingelheim To Present New Phase II Clinical Data On Two Lead Oncology Compounds At ASCO 2009
- New Treatment Option At The Sarah Cannon Cancer Center Provides Hope For Inoperable Tumors
- New Publication Indian Journal Of Surgical Oncology To Be Launched By Springer
- SuperGen's MP-470 Demonstrates Clinical Benefit In Lung Cancer Patients
- Study Provides Documentation That Tumor Stem-like Cells Exist In Benign Tumors
- Prostate Cancer-specific Mortality After Radical Prostatectomy For Patients Treated In The Prostate-specific Antigen Era
- Childhood Cancer Cases And Common Household Pesticides Linked In Washington Area
- Get Screened: Early Detection Is The Key To Successful Skin Cancer Treatment
- Colon Cancer Alliance Statement Regarding CMS' Decision To Not Cover Virtual Colonoscopies
- Cancer Deaths Second Only to Suicide in Schizophrenia (CME/CE)
Prescription Cancer Drugs
High-Risk Populations For Bladder-Cancer Screenings Investigated By UT Southwestern Researchers
Posted by: admin in Prescription Cancer Drugs on July 23rd, 2009
A new study by UT Southwestern Medical Center researchers sheds light on the challenges involved in identifying which high-risk population would benefit most from bladder-cancer screening.
Large-scale screening of people at high risk for developing invasive bladder cancer could result in earlier diagnosis and improved survival rates. Bladder cancer is the fourth most common cancer in men and the fifth most common cancer overall. In the early stages of the disease, it’s common to have no signs or symptoms. Smoking has been proven to increase the risk of the disease.
“At this time bladder cancer screening is not the standard of care,” said Dr. Yair Lotan, associate professor of urology and senior author of the study appearing online and in a future edition of The Journal of Urology. “Although progress has been made in diagnosis, those efforts have translated into minimal survival benefit. In order to get the most benefit from the added cost of screening, we need to identify the appropriate population to screen.”
In the study researchers used a point-of-care urine-based test called NMP22 BladderChek to screen 1,502 subjects without symptoms who are at high risk for bladder cancer based on age, smoking history and occupational exposure.
Patients for the study were recruited from well-patient clinics at UT Southwestern and the Dallas Veterans Affairs Health Care System from March 2006 to November 2007. Those selected were over 50 years old, had smoked for 10 years or more, or had worked for 15 years or more in a high-risk occupation, such as in the dye, petroleum or chemical industries. Participants with other conditions that might lead to false-positive tests were excluded from the study.
Of the 1,502 participants, 85 tested positive for proteins that indicate the possible presence of a bladder tumor; 69 of those agreed to undergo cystoscopy. Only two, however, were found to have noninvasive bladder cancer. The majority of these participants had undergone urinalysis within three years of screening. At the one-year follow-up, two more were found to have cancer, and these patients were over 60 and had more than 42 pack-years of smoking.
“We did expect to find more cases,” Dr. Lotan said. “The significance is that even with high-risk patients, only a few had cancer. What that means is we need to find a higher-risk group either by increasing screening to over the age of 60 instead of 50 or looking at individuals with a longer smoking history.”
Dr. Lotan said that abstaining from or quitting smoking is the most effective way to prevent bladder cancer and that people should see a urologist immediately if they see blood in their urine or are found to have microscopic blood in their urine.
Other UT Southwestern researchers involved in the study were Dr. Arthur Sagalowsky, professor of urology; Dr. Brett Moran, associate professor of internal medicine; Dr. Geoffrey Nuss, urology resident; Dr. Aditya Bagrodia, family practice resident; Keren Elias, research study coordinator; and Dr. Robert Svatek, a fellow in urologic oncology at UT M.D. Andersen Cancer Center.
Source:
Erin Prather Stafford
UT Southwestern Medical Center
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.





